You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A simple assay system for rapid detection of circulating tumor cells
SBC: TELOVISION, LLC Topic: NCIDESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Silica Colloidal Crystals for High Resolution MALDI-MS of Glycoproteins
SBC: LI-COR, Inc. Topic: 100DESCRIPTION provided by applicant The product is a slide coated with silica colloidal crystals to combine protein electrophoresis with matrix assisted laser desorption ionization mass spectrometry MALDI MS detection giving superior performance in both The Phase II proposal will be to develop an instrument for facile application of the slide in proteomics of intat glycoproteins This propos ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 300DESCRIPTION provided by applicant Mass spectrometry based proteomics is an emerging technology that has seen possible applications everywhere The technique can potentially use one drop of our blood to reveal onset and progress of diseases Current Randamp D using plasma serum proteome sample sets however is severely limited by the high complexity and dynamic range of protein concentrations ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Universal amplifier system for high-fidelity multi-modal biosignal recordings
SBC: REFER2INPUT, LLC Topic: 213DESCRIPTION provided by applicant The measurement monitoring and use of bioelectric signals has evolved from the measurement of the electrical activity of the heart to encompass tissues ranging from cardiac skeletal and smooth muscles to brain and peripheral nerve tissues Together with this development has been the evolution of specialized equipment to capture and interpret these minute sig ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Operating Room Efficiency
SBC: ADVANCED PROCESS COMBINATORICS, INC. Topic: NIBIBDESCRIPTION (provided by applicant): Optimal use of operating room (OR) personnel and resources is an important problem from multiple perspectives. Unanticipated waits and delays continue to add tremendous costs and negatively impact outcomes. There are over 55 million ambulatory and 45 million inpatient procedures performed in the U.S. annually, with increasing case complexities and patient comor ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Nanocrystal Delivery of Hydrophobic Anticancer Drugs
SBC: PDS Biotechnology Corporation Topic: NIBIBDESCRIPTION (provided by applicant): Nanosystems have been extensively investigated for drug delivery; however, there is a challenge in transferring nanotechnology from research laboratories into pharmaceutical industry. The scientific basis for this proposal originated from our three-phase nanoparticle engineering (3PNE) method recently developed which includes phase 1, amorphous precipitate; p ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral Vectors for the Treatment of Fanconi Anemia
SBC: Rimedion, Inc. Topic: NHLBIDESCRIPTION (provided by applicant): HIV-1 based lentiviral vectors are becoming an increasingly attractive means of integrating transgenes into target cells. Vectors are in or enterning clinical trials for a diverse group of ailments, including genetic disease, AIDS and cancer. Rimedion and its research partner, Indiana University School of Medicine proposes to develop a novel lentiviral vector f ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Packaging Cell Lines for Lentiviral Vector Products
SBC: Rimedion, Inc. Topic: NCRRDESCRIPTION (provided by applicant): HIV-1 based lentiviral vectors are becoming an increasingly attractive means of integrating transgenes into target cells. Vectors are in or enterning clinical trials for a diverse group of ailments, including genetic disease, AIDS and cancer. To expand the range of target cells beyond that of HIV-1 (CD4+ cells), vectors are pseudotyped with various viral envelo ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Continuous monitoring of anti-fibrinolytic therapy in cardiovascular surgery
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only FDA approved and most commonly used inhibitor of PLact in cardiovascular surgery, while eff ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health